An interventional study of Model 400 aortic valve bioprosthesis in Aortic Stenosis, sponsored by Medtronic Cardiac Surgery. Active, not recruiting at 38 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-29.
Sponsored by Medtronic Cardiac Surgery (part of Medtronic) · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 34 studies in Aortic Valve Stenosis by Medtronic — 1 open to participants now, 6 under way, none of them phase 3. Aortic Valve Stenosis · Medtronic.
Among the 34 studies in Aortic Valve Stenosis by Medtronic, this one is the 5th largest by enrollment of the 20 interventional ones that give a count, is one of 4 that started in 2014, is one of 20 with no phase, and was the 19th registered.
1,028 studies on the registry are indexed under Aortic Valve Stenosis; 295 are open to participants now.
Browse Aortic Valve Stenosis studies →1 of the 34 studies in Aortic Valve Stenosis by Medtronic is open now, in 1 country. Recruiting first, the newest first:
Medtronic Cardiovascular · Sites in United States
Ages 18–105
By country, each count listing its studies:
Of the 209 Aortic Valve Stenosis studies recruiting now, 163 (78%) set no upper age limit and 9 (4%) stop at 75 or younger; 24 take children under 18; 14 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
34 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 4 started in 2014.
This study's enrollment of 1,312 is above the median of 126 across 555 interventional studies indexed under Aortic Valve Stenosis.
Median enrollment 109 across the 20 interventional studies, 214 across the 14 observational. Of the 28 that completed or were terminated, 18 (64%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Medtronic Cardiac Surgery, one of the names counted as Medtronic. Under that name alone:
Medtronic Cardiac Surgery is the lead sponsor of 9 studies on the registry; 3 are open to participants now.
1 of the studies in Aortic Valve Stenosis by Medtronic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06777368Medtronic CardiovascularREdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE | 2027-11 |
Add it to your calendar (.ics) → With an account.
Among the 34 studies in Aortic Valve Stenosis by Medtronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and effectiveness of the Model 400 aortic valve bioprosthesis.
This is a prospective, interventional, non-randomized, worldwide, multi-center trial. A maximum of 1300 subjects were to be implanted at a maximum of 40 sites in the US, Europe and Canada. The trial includes male and female patients of legal age to provide informed consent in the country where they enrolled in the trial, requiring replacement for a diseased, damaged, or malfunctioning native or prosthetic aortic valve. Subjects are followed out to 5 years, and select sites follow subjects out to 12 years. Enrollment closed on 14Jul2017 for all valve sizes. Enrollment was reopened in Apr2019 for the 29mm valve size at a subset of US and Canadian sites to obtain greater patient numbers required by the FDA to support US commercial approval of this valve size. Enrollment for the 29mm valve size closed on 14Feb2023.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient has moderate or greater aortic stenosis or regurgitation, and there is clinical indication for replacement of their native or prosthetic aortic valve with a bioprosthesis, with or without concomitant procedures, which are limited to any of the following:
i. Left atrial appendage (LAA) ligation ii. CABG (coronary artery bypass grafting) iii. Patent foramen ovale (PFO) closure iv. Ascending aortic aneurysm or dissection repair not requiring circulatory arrest v. Resection of a sub-aortic membrane not requiring myectomy
Exclusion Criteria:
Patient has an anatomical abnormality which would increase surgical risk of morbidity or mortality, including:
Patient has a non-cardiac major or progressive disease, with a of less than 2 years. These conditions include, but are not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Model 400 aortic valve bioprosthesis
Evaluate the Safety of the Model 400 Avalus Valve With Regard to Valve-related Adverse Events and Death at 1 Year Post-implant
Safety of the valve is evaluated by the time-related incidence of valve-related adverse events and death. The following valve-related adverse events are evaluated in this study: Thromboembolism, Thrombosis, Hemorrhage, Paravalvular leak (PVL), Endocarditis, Hemolysis, Structural valve deterioration, Non-structural dysfunction, Reintervention, Explant, and Death. A minimum of 15 participants per valve size are evaluated. The incidence rates will be used to summarize valve-related adverse events and death.
Time frame: 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Change of New York Heart Association (NYHA) Classification From Baseline Through 1 Year
At each timepoint, a minimum of 15 participants per valve size evaluated for change in New York Heart Association (NYHA) functional classification from baseline to 1 year post-procedure. Measure Description: Cardiac Disease with Functional Classes (lower value is more desirable than higher value) I - No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. II - Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. III - Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. IV - Symptoms of heart failure at rest. Any physical activity causes further discomfort.
Time frame: Discharge (up to 30 days), 3-6 months, and 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Effective Orifice Area Through 1 Year Post-procedure
A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.
Time frame: Discharge (up to 30 days), 3-6 months, 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Effective Orifice Area Index (EOAI) Through 1 Year Post-implant
A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.
Time frame: Discharge (up to 30 days), 3-6 months, and 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Peak Pressure Gradient (mmHg) From Discharge up to 1 Year
A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.
Time frame: Measured at discharge (up to 30 days), 3-6 months, and 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Mean Pressure Gradient (mmHg) Through 1 Year Post-implant
A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.
Time frame: Discharge (up to 30 days), 3-6 months, and 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Performance Index (L/Min) Through 1 Year Post-implant
A minimum of 15 participants per valve size will have performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.
Time frame: Discharge (up to 30 days), 3-6 months, and 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Output (L/Min) Through 1 Year Post-implant
Cardiac output is the amount of blood pumped by the heart per minute. A minimum of 15 participants per valve size were evaluated for this outcome measure by transthoracic echocardiography technique and assessed by an independent core laboratory.
Time frame: Discharge (up to 30 days), 3-6 months, and 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Index (L/Min/m^2) Through 1 Year Post-implant
A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.
Time frame: Discharge (up to 30 days), 3-6 months, and 1 year post-implant
Evaluate the Safety of the Model 400 Avalus Valve With Regard to Valve-related Adverse Events and Death Annually Through 5 Years Post-implant
Safety of the valve is evaluated by the time-related incidence of valve-related adverse events and death. The following valve-related adverse events are evaluated in this study: Thromboembolism, Thrombosis, Hemorrhage, Paravalvular leak (PVL), Endocarditis, Hemolysis, Structural valve deterioration, Non-structural dysfunction, Reintervention, Explant, and Death. The Kaplan-Meier event rates will be used to summarize valve-related adverse events and death. The Kaplan-Meier rate and the corresponding 95% confidence interval will be presented for each visit interval.
Time frame: Annually, at years 2, 3, 4, and 5 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Change of New York Heart Association (NYHA) Classification From Baseline Through 5 Years Post-implant
At each timepoint, participants were evaluated for change in New York Heart Association (NYHA) functional classification from baseline through 5 years post-procedure. Measure Description: Cardiac Disease with Functional Classes (lower value is more desirable than higher value) I - No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. II - Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. III - Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. IV - Symptoms of heart failure at rest. Any physical activity causes further discomfort.
Time frame: Annually, at years 2, 3, 4, and 5 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Effective Orifice Area Through 5 Years Post-procedure
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.
Time frame: Annually, at years 2, 3, 4, and 5 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Effective Orifice Area Index (EOAI) Through 5 Years Post-implant
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.
Time frame: Annually, at years 2, 3, 4, and 5 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Peak Pressure Gradient (mmHg) From Discharge up to 5 Years Post-implant
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.
Time frame: Annually, at years 2, 3, 4, and 5 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Mean Pressure Gradient (mmHg) Through 5 Years Post-implant
Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.
Time frame: Annually, at years 2, 3, 4, and 5 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Performance Index (L/Min) Through 5 Years Post-implant
Performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.
Time frame: Annually, at years 2, 3, 4, and 5 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Output (L/Min) Through 5 Years Post-implant
Cardiac output is the amount of blood pumped by the heart per minute, evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory.
Time frame: Annually, at years 2, 3, 4, and 5 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Index (L/Min/m^2) Through 5 Years Post-implant
Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.
Time frame: Annually, at years 2, 3, 4, and 5 post-implant
Evaluate the Safety of the Model 400 Avalus Valve With Regard to Valve-related Adverse Events and Death at 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)
Safety of the valve is evaluated by the time-related incidence of valve-related adverse events and death. The following valve-related adverse events are evaluated in this study: Thromboembolism, Thrombosis, Hemorrhage, Paravalvular leak (PVL), Endocarditis, Hemolysis, Structural valve deterioration, Non-structural dysfunction, Reintervention, Explant, and Death. A minimum of 15 participants per valve size are evaluated. The Kaplan-Meier event rates will be used to summarize valve-related adverse events and death. The Kaplan-Meier rate and the corresponding 95% confidence interval will be presented for each visit interval.
Time frame: 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Change of New York Heart Association (NYHA) Classification From Baseline Through 1 Year (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)
Participants evaluated for change in New York Heart Association (NYHA) functional classification from baseline to 1 year post-procedure. Measure Description: Cardiac Disease with Functional Classes (lower value is more desirable than higher value) I - No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. II - Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. III - Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. IV - Symptoms of heart failure at rest. Any physical activity causes further discomfort.
Time frame: 3-6 months and 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Effective Orifice Area Through 1 Year Post-procedure (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.
Time frame: 3-6 months, 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Effective Orifice Area Index (EOAI) Through 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.
Time frame: 3-6 months, and 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Peak Pressure Gradient (mmHg) From Discharge up to 1 Year (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.
Time frame: 3-6 months, and 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Mean Pressure Gradient (mmHg) Through 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)
Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.
Time frame: 3-6 months, and 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Performance Index (L/Min) Through 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)
Performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.
Time frame: 3-6 months, and 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Output (L/Min) Through 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)
Cardiac output is the amount of blood pumped by the heart per minute. Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory.
Time frame: 3-6 months, and 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Index (L/Min/m^2) Through 1 Year Post-implant (Remaining Data From 29mm Valve Participants Not Required for Meeting Primary Outcomes)
Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.
Time frame: 3-6 months, and 1 year post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve by Clinically Acceptable Hemodynamic Performance From Years 6 Through 12 Post-implant.
Long-term follow-up clinically acceptable hemodynamic performance defined as freedom from surgical explant and/or percutaneous valve-in-valve reintervention due to structural valve deterioration
Time frame: Annually, years 6-12 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve From Years 6 - 12 Post-implant by Freedom From Valve-related Death
Time frame: Annually, years 6 though 12 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve From Years 6 - 12 Post-implant by Freedom From All-cause Mortality
For time-to-event outcomes, Kaplan-Meier (actuarial) analysis of the event-free rate performed annually through twelve years.
Time frame: Annually, years 6 though 12 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve From Years 6 - 12 Post-implant by Change in NYHA Functional Classification Status From Baseline
Time frame: Annually, years 6 though 12 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Effective Orifice Area Through 12 Years Post-procedure
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.
Time frame: Annually, years 6 though 12 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Effective Orifice Area Index (EOAI) Through 12 Years Post-implant
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.
Time frame: Annually, years 6 though 12 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to the Peak Pressure Gradient (mmHg) up to 12 Years Post-implant
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.
Time frame: Annually, years 6 though 12 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Mean Pressure Gradient (mmHg) Through 12 Years Post-implant
Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.
Time frame: Annually, years 6 though 12 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Performance Index (L/Min) Through 12 Years Post-implant
Performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.
Time frame: Annually, years 6 though 12 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Output (L/Min) Through 12 Years Post-implant
Cardiac output is the amount of blood pumped by the heart per minute. Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory.
Time frame: Annually, years 6 though 12 post-implant
Confirm the Effectiveness of the Model 400 Avalus Valve With Regard to Cardiac Index (L/Min/m^2) Through 12 Years Post-implant
Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.
Time frame: Annually, years 6 though 12 post-implant
| Milestone | Medtronic Model 400 Avalus Bioprosthetic Aortic Valve |
|---|---|
| Started | 1312 |
| Implanted | 1132 |
| 1 year completion | 1050 |
| Completed | 268 |
| Not completed | 1044 |
| Withdrew: Exited before procedure | 130 |
| Withdrew: Attempted but not implanted | 31 |
| Withdrew: Implant not attempted | 19 |
| Withdrew: Pending next visit | 532 |
| Withdrew: Death | 170 |
| Withdrew: Subject withdrew + physician withdrew + subject not implanted with study valve | 96 |
| Withdrew: Lost to follow-up | 23 |
| Withdrew: Explanted | 32 |
| Withdrew: Any other reason not covered by previous categories | 11 |
Safety of the valve is evaluated by the time-related incidence of valve-related adverse events and death. The following valve-related adverse events are evaluated in this study: Thromboembolism, Thrombosis, Hemorrhage, Paravalvular leak (PVL), Endocarditis, Hemolysis, Structural valve deterioration, Non-structural dysfunction, Reintervention, Explant, and Death. A minimum of 15 participants per valve size are evaluated. The incidence rates will be used to summarize valve-related adverse events and death.
| percentage of participants with event | Medtronic Avalus Valve 19mm | Medtronic Avalus Valve 21mm | Medtronic Avalus Valve 23mm | Medtronic Avalus Valve 25mm | Medtronic Avalus Valve 27mm | Medtronic Avalus Valve 29mm | Medtronic Avalus Valve (17mm - 29mm) |
|---|---|---|---|---|---|---|---|
| All death | 9.5 | 2.8 | 2.2 | 2.9 | 4.0 | 3.8 | 3.0 |
| Valve- related death | 0.0 | 0.9 | 0.2 | 0.0 | 0.0 | 0.0 | 0.3 |
| Thromboembolism | 0.0 | 2.8 | 2.7 | 2.9 | 4.0 | 3.8 | 2.8 |
| Valve thrombosis | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| All hemorrhage | 7.1 | 3.8 | 6.7 | 4.3 | 7.9 | 0.0 | 5.4 |
| Major hemorrhage | 7.1 | 0.5 | 5.0 | 3.4 | 5.0 | 0.0 | 3.6 |
| All paravalvular leak | 0.0 | 0.5 | 0.5 | 0.6 | 1.0 | 0.0 | 0.5 |
| Major paravalvular leak | 0.0 | 0.5 | 0.0 | 0.3 | 0.0 | 0.0 | 0.2 |
| Endocarditis | 0.0 | 0.5 | 1.5 | 1.4 | 1.0 | 0.0 | 1.1 |
| Hemolysis | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Non-structural valve dysfunction | 0.0 | 0.5 | 0.5 | 0.6 | 1.0 | 0.0 | 0.5 |
| Structural valve deterioration | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Severe hemodynamic dysfunction - indeterminate or evolving cause | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Reintervention | 0.0 | 0.9 | 1.2 | 0.6 | 1.0 | 0.0 | 0.9 |
| Explant | 0.0 | 0.9 | 1.2 | 0.6 | 1.0 | 0.0 | 0.9 |
At each timepoint, a minimum of 15 participants per valve size evaluated for change in New York Heart Association (NYHA) functional classification from baseline to 1 year post-procedure. Measure Description: Cardiac Disease with Functional Classes (lower value is more desirable than higher value) I - No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. II - Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. III - Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. IV - Symptoms of heart failure at rest. Any physical activity causes further discomfort.
| Participants | Medtronic Avalus Valve 19mm | Medtronic Avalus Valve 21mm | Medtronic Avalus Valve 23mm | Medtronic Avalus Valve 25mm | Medtronic Avalus Valve 27mm | Medtronic Avalus Valve 29mm | Medtronic Avalus Valve (17mm - 29mm) |
|---|---|---|---|---|---|---|---|
| Discharge up to 30 days — Improved 3 Classes | 0 | 0 | 5 | 2 | 2 | 0 | 9 |
| Discharge up to 30 days — Improved 2 Classes | 5 | 14 | 30 | 27 | 9 | 1 | 86 |
| Discharge up to 30 days — Improved 1 Class | 21 | 83 | 131 | 108 | 26 | 12 | 382 |
| Discharge up to 30 days — No Change | 12 | 61 | 118 | 116 | 23 | 7 | 337 |
| Discharge up to 30 days — Worsened 1 Class | 0 | 15 | 16 | 18 | 10 | 3 | 62 |
| Discharge up to 30 days — Worsened 2 Classes | 0 | 1 | 2 | 1 | 0 | 0 | 4 |
| Discharge up to 30 days — Worsened 3 Classes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-6 Months — Improved 3 Classes | 0 | 1 | 4 | 6 | 1 | 0 | 12 |
| 3-6 Months — Improved 2 Classes | 15 | 51 | 103 | 82 | 27 | 4 | 282 |
| 3-6 Months — Improved 1 Class | 20 | 97 | 187 | 164 | 43 | 13 | 525 |
| 3-6 Months — No Change | 5 | 47 | 76 | 79 | 25 | 4 | 236 |
| 3-6 Months — Worsened 1 Class | 0 | 2 | 9 | 5 | 1 | 1 | 18 |
| 3-6 Months — Worsened 2 Classes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-6 Months — Worsened 3 Classes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 Year — Improved 3 Classes | 0 | 1 | 6 | 6 | 0 | 0 | 13 |
| 1 Year — Improved 2 Classes | 13 | 60 | 105 | 79 | 27 | 4 | 289 |
| 1 Year — Improved 1 Class | 16 | 83 | 176 | 161 | 40 | 10 | 486 |
| 1 Year — No Change | 8 | 47 | 76 | 70 | 26 | 3 | 230 |
| 1 Year — Worsened 1 Class | 0 | 5 | 6 | 6 | 0 | 0 | 17 |
| 1 Year — Worsened 2 Classes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 1 Year — Worsened 3 Classes | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.
| cm^2 | Medtronic Avalus Valve 19mm | Medtronic Avalus Valve 21mm | Medtronic Avalus Valve 23mm | Medtronic Avalus Valve 25mm | Medtronic Avalus Valve 27mm | Medtronic Avalus Valve 29mm | Medtronic Avalus Valve (17mm - 29mm) |
|---|---|---|---|---|---|---|---|
| Discharge (up to 30 days) | 1.23 ± 0.24 | 1.35 ± 0.30 | 1.59 ± 0.34 | 1.68 ± 0.37 | 1.88 ± 0.42 | 2.29 ± 0.68 | 1.60 ± 0.40 |
| 3-6 Months | 1.22 ± 0.27 | 1.30 ± 0.26 | 1.54 ± 0.30 | 1.66 ± 0.32 | 1.89 ± 0.42 | 2.51 ± 0.71 | 1.57 ± 0.39 |
| 1 Year | 1.09 ± 0.23 | 1.26 ± 0.25 | 1.48 ± 0.33 | 1.60 ± 0.34 | 1.76 ± 0.35 | 2.42 ± 0.59 | 1.50 ± 0.38 |
A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.
| cm^2/m^2 | Medtronic Avalus Valve 19mm | Medtronic Avalus Valve 21mm | Medtronic Avalus Valve 23mm | Medtronic Avalus Valve 25mm | Medtronic Avalus Valve 27mm | Medtronic Avalus Valve 29mm | Medtronic Avalus Valve (17mm - 29mm) |
|---|---|---|---|---|---|---|---|
| Discharge (up to 30 days) | 0.71 ± 0.16 | 0.74 ± 0.18 | 0.81 ± 0.20 | 0.81 ± 0.19 | 0.89 ± 0.23 | 1.07 ± 0.3 | 0.81 ± 0.20 |
| 3-6 Months | 0.71 ± 0.17 | 0.72 ± 0.16 | 0.79 ± 0.17 | 0.81 ± 0.17 | 0.90 ± 0.22 | 1.16 ± 0.31 | 0.80 ± 0.19 |
| 1 Year | 0.63 ± 0.14 | 0.70 ± 0.15 | 0.76 ± 0.18 | 0.78 ± 0.17 | 0.82 ± 0.17 | 1.14 ± 0.28 | 0.76 ± 0.18 |
A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.
| mmHg | Medtronic Avalus Valve 19mm | Medtronic Avalus Valve 21mm | Medtronic Avalus Valve 23mm | Medtronic Avalus Valve 25mm | Medtronic Avalus Valve 27mm | Medtronic Avalus Valve 29mm | Medtronic Avalus Valve (17mm - 29mm) |
|---|---|---|---|---|---|---|---|
| Discharge (up to 30 days) | 32.2 ± 9.7 | 28.0 ± 9.2 | 23.6 ± 8.0 | 22.4 ± 6.8 | 19.6 ± 6.8 | 16.2 ± 6.3 | 23.9 ± 8.4 |
| 3-6 Months | 27.2 ± 6.7 | 26.3 ± 8.6 | 21.6 ± 6.8 | 21.1 ± 7.2 | 17.7 ± 5.9 | 14.7 ± 6.3 | 22.1 ± 7.7 |
| 1 Year | 30.4 ± 8.2 | 27.8 ± 9.4 | 23.1 ± 7.5 | 22.0 ± 7.3 | 19.0 ± 6.7 | 18.1 ± 6.5 | 23.5 ± 8.3 |
A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.
| mmHg | Medtronic Avalus Valve 19mm | Medtronic Avalus Valve 21mm | Medtronic Avalus Valve 23mm | Medtronic Avalus Valve 25mm | Medtronic Avalus Valve 27mm | Medtronic Avalus Valve 29mm | Medtronic Avalus Valve (17mm - 29mm) |
|---|---|---|---|---|---|---|---|
| Discharge (up to 30 days) | 18.2 ± 6.1 | 15.2 ± 4.9 | 12.9 ± 4.5 | 12.4 ± 3.9 | 10.7 ± 3.8 | 8.8 ± 3.5 | 13.1 ± 4.7 |
| 3-6 Months | 15.4 ± 4.4 | 14.2 ± 4.6 | 11.7 ± 3.7 | 11.3 ± 3.7 | 9.6 ± 3.3 | 7.9 ± 3.6 | 11.9 ± 4.1 |
| 1 Year | 17.1 ± 5.0 | 15.1 ± 5.3 | 12.3 ± 4.0 | 11.9 ± 4.0 | 10.1 ± 3.7 | 10.2 ± 3.5 | 12.7 ± 4.6 |
A minimum of 15 participants per valve size will have performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.
| L/min | Medtronic Avalus Valve 19mm | Medtronic Avalus Valve 21mm | Medtronic Avalus Valve 23mm | Medtronic Avalus Valve 25mm | Medtronic Avalus Valve 27mm | Medtronic Avalus Valve 29mm | Medtronic Avalus Valve (17mm - 29mm) |
|---|---|---|---|---|---|---|---|
| Discharge (up to 30 days) | 0.5 ± 0.1 | 0.5 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 |
| 3-6 Months | 0.5 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 |
| 1 Year | 0.5 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 | 0.3 ± 0.1 | 0.4 ± 0.1 | 0.4 ± 0.1 |
Cardiac output is the amount of blood pumped by the heart per minute. A minimum of 15 participants per valve size were evaluated for this outcome measure by transthoracic echocardiography technique and assessed by an independent core laboratory.
| L/min | Medtronic Avalus Valve 19mm | Medtronic Avalus Valve 21mm | Medtronic Avalus Valve 23mm | Medtronic Avalus Valve 25mm | Medtronic Avalus Valve 27mm | Medtronic Avalus Valve 29mm | Medtronic Avalus Valve (17mm - 29mm) |
|---|---|---|---|---|---|---|---|
| Discharge (up to 30 days) | 5.0 ± 1.0 | 4.9 ± 1.2 | 5.1 ± 1.3 | 5.2 ± 1.2 | 5.3 ± 1.4 | 5.2 ± 1.2 | 5.1 ± 1.3 |
| 3-6 Months | 4.6 ± 1.1 | 4.5 ± 0.9 | 4.8 ± 1.0 | 4.9 ± 1.1 | 4.9 ± 1.2 | 5.8 ± 1.7 | 4.8 ± 1.1 |
| 1 Year | 4.3 ± 1.0 | 4.5 ± 1.1 | 4.7 ± 1.1 | 4.9 ± 1.2 | 4.8 ± 1.0 | 6.4 ± 2.0 | 4.7 ± 1.2 |
A minimum of 15 participants per valve size evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.
| L/min/m^2 | Medtronic Avalus Valve 19mm | Medtronic Avalus Valve 21mm | Medtronic Avalus Valve 23mm | Medtronic Avalus Valve 25mm | Medtronic Avalus Valve 27mm | Medtronic Avalus Valve 29mm | Medtronic Avalus Valve (17mm - 29mm) |
|---|---|---|---|---|---|---|---|
| Discharge (up to 30 days) | 2.9 ± 0.7 | 2.7 ± 0.7 | 2.6 ± 0.7 | 2.5 ± 0.6 | 2.5 ± 0.7 | 2.4 ± 0.6 | 2.6 ± 0.7 |
| 3-6 Months | 2.7 ± 0.7 | 2.5 ± 0.5 | 2.4 ± 0.5 | 2.4 ± 0.5 | 2.3 ± 0.6 | 2.7 ± 0.7 | 2.4 ± 0.5 |
| 1 Year | 2.5 ± 0.5 | 2.5 ± 0.6 | 2.4 ± 0.5 | 2.4 ± 0.6 | 2.2 ± 0.4 | 3.0 ± 0.8 | 2.4 ± 0.6 |
Safety of the valve is evaluated by the time-related incidence of valve-related adverse events and death. The following valve-related adverse events are evaluated in this study: Thromboembolism, Thrombosis, Hemorrhage, Paravalvular leak (PVL), Endocarditis, Hemolysis, Structural valve deterioration, Non-structural dysfunction, Reintervention, Explant, and Death. The Kaplan-Meier event rates will be used to summarize valve-related adverse events and death. The Kaplan-Meier rate and the corresponding 95% confidence interval will be presented for each visit interval.
Results for this outcome have not been posted.
At each timepoint, participants were evaluated for change in New York Heart Association (NYHA) functional classification from baseline through 5 years post-procedure. Measure Description: Cardiac Disease with Functional Classes (lower value is more desirable than higher value) I - No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. II - Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. III - Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. IV - Symptoms of heart failure at rest. Any physical activity causes further discomfort.
Results for this outcome have not been posted.
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.
Results for this outcome have not been posted.
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.
Results for this outcome have not been posted.
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.
Results for this outcome have not been posted.
Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.
Results for this outcome have not been posted.
Performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.
Results for this outcome have not been posted.
Cardiac output is the amount of blood pumped by the heart per minute, evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory.
Results for this outcome have not been posted.
Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.
Results for this outcome have not been posted.
Safety of the valve is evaluated by the time-related incidence of valve-related adverse events and death. The following valve-related adverse events are evaluated in this study: Thromboembolism, Thrombosis, Hemorrhage, Paravalvular leak (PVL), Endocarditis, Hemolysis, Structural valve deterioration, Non-structural dysfunction, Reintervention, Explant, and Death. A minimum of 15 participants per valve size are evaluated. The Kaplan-Meier event rates will be used to summarize valve-related adverse events and death. The Kaplan-Meier rate and the corresponding 95% confidence interval will be presented for each visit interval.
Results for this outcome have not been posted.
Participants evaluated for change in New York Heart Association (NYHA) functional classification from baseline to 1 year post-procedure. Measure Description: Cardiac Disease with Functional Classes (lower value is more desirable than higher value) I - No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation or shortness of breath. II - Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. III - Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. IV - Symptoms of heart failure at rest. Any physical activity causes further discomfort.
Results for this outcome have not been posted.
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.
Results for this outcome have not been posted.
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.
Results for this outcome have not been posted.
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.
Results for this outcome have not been posted.
Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.
Results for this outcome have not been posted.
Performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.
Results for this outcome have not been posted.
Cardiac output is the amount of blood pumped by the heart per minute. Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory.
Results for this outcome have not been posted.
Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.
Results for this outcome have not been posted.
Long-term follow-up clinically acceptable hemodynamic performance defined as freedom from surgical explant and/or percutaneous valve-in-valve reintervention due to structural valve deterioration
Results for this outcome have not been posted.
Results for this outcome have not been posted.
For time-to-event outcomes, Kaplan-Meier (actuarial) analysis of the event-free rate performed annually through twelve years.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The effective orifice area (EOA) is measured as the minimal cross-sectional area of the blood flow downstream of the aortic valve.
Results for this outcome have not been posted.
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory for effective orifice area index (EOAI = EOA/BSA) Effective orifice area index is equal to the effective orifice area (EOA) in cm\^2 divided by body surface area (BSA) in m\^2. The achievement criterion for the effective orifice area index (EOAI) is defined to be ≥0.6 cm\^2/m\^2 12 months after the procedure. This criterion is in accordance with the definition of severe aortic stenosis in the American College of Cardiology (ACC) / American Heart Association (AHA) guidelines for the management of valvular heart disease.
Results for this outcome have not been posted.
Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory. The peak pressure gradient is the maximum value measured of flow of blood through the aortic valve as measured in millimeters of mercury.
Results for this outcome have not been posted.
Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The mean pressure gradient is the average flow of blood through the aortic valve measured in millimeters of mercury.
Results for this outcome have not been posted.
Performance index (L/Min) measured by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The performance index is the measurement of the effective orifice area divided by the native orifice area.
Results for this outcome have not been posted.
Cardiac output is the amount of blood pumped by the heart per minute. Evaluated by transthoracic echocardiography technique and assessed by an independent core laboratory.
Results for this outcome have not been posted.
Evaluated by transthoracic echocardiography technique and will be assessed by an independent core laboratory. The cardiac index is an assessment of the cardiac output based on a patient's size measured by dividing the cardiac output by the patient's body's surface area.
Results for this outcome have not been posted.
Collected over Site reported adverse events and serious adverse events data collected from implant through 1 year.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Medtronic Avalus Valve (All Valve Sizes) | 170/1,132 (15%) | 638/1,132 (56.4%) | 1,105/1,132 (97.6%) |
| Event | Medtronic Avalus Valve (All Valve Sizes) |
|---|---|
| Supraventricular ArrhythmiasCardiac disorders | 146/1132 |
| Pneumothorax And Pleural Effusions NecRespiratory, thoracic and mediastinal disorders | 111/1132 |
| Anaemias NecBlood and lymphatic system disorders | 98/1132 |
| Non-Site Specific Procedural ComplicationsInjury, poisoning and procedural complications | 55/1132 |
| Cardiac Conduction DisordersCardiac disorders | 49/1132 |
| Pericardial Disorders NecCardiac disorders | 49/1132 |
| Heart Failures NecCardiac disorders | 43/1132 |
| Respiratory Failures (Excl Neonatal)Respiratory, thoracic and mediastinal disorders | 40/1132 |
| Renal Failure And ImpairmentRenal and urinary disorders | 38/1132 |
| Central Nervous System Haemorrhages And Cerebrovascular AccidentsNervous system disorders | 37/1132 |
| Event | Medtronic Avalus Valve (All Valve Sizes) |
|---|---|
| Supraventricular ArrhythmiasCardiac disorders | 674/1132 |
| Anaemias NecBlood and lymphatic system disorders | 420/1132 |
| Cardiac Conduction DisordersCardiac disorders | 396/1132 |
| Pneumothorax And Pleural Effusions NecRespiratory, thoracic and mediastinal disorders | 387/1132 |
| Non-Site Specific Procedural ComplicationsInjury, poisoning and procedural complications | 276/1132 |
| ThrombocytopeniasBlood and lymphatic system disorders | 255/1132 |
| Vascular Hypotensive DisordersVascular disorders | 225/1132 |
| Hyperglycaemic Conditions NecMetabolism and nutrition disorders | 220/1132 |
| Oedema NecGeneral disorders | 183/1132 |
| Pericardial Disorders NecCardiac disorders | 167/1132 |
| Age, Continuous(years) | Medtronic Model 400 Avalus Bioprosthetic Aortic Valve |
|---|---|
| Mean | 70.1 ± 8.9 |
| Sex: Female, Male(Participants) | Medtronic Model 400 Avalus Bioprosthetic Aortic Valve |
|---|---|
| Female | 278 |
| Male | 854 |
| Ethnicity (NIH/OMB)(Participants) | Medtronic Model 400 Avalus Bioprosthetic Aortic Valve |
|---|---|
| Hispanic or Latino | 19 |
| Not Hispanic or Latino | 638 |
| Unknown or Not Reported | 475 |
| Race (NIH/OMB)(Participants) | Medtronic Model 400 Avalus Bioprosthetic Aortic Valve |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 11 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 9 |
| White | 636 |
| More than one race | 0 |
| Unknown or Not Reported | 476 |
| Region of Enrollment(participants) | Medtronic Model 400 Avalus Bioprosthetic Aortic Valve |
|---|---|
| Canada | 268 |
| Europe | 475 |
| United States | 389 |
| New York Heart Association (NYHA) Classification(Participants) | Medtronic Model 400 Avalus Bioprosthetic Aortic Valve |
|---|---|
| NYHA Class I | 126 |
| NYHA Class II | 533 |
| NYHA Class III | 451 |
| NYHA Class IV | 22 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2014 to primary completion in Apr 2023, 107 months.
Results were first posted in Jun 2024, 1 year 1 month after primary completion.
Of 111 industry-sponsored interventional studies with no phase under Aortic Valve Stenosis, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 54. This study's 107 months is above that.
Counting every sponsor, half of 288 studies reached it within 33 months; a quarter within 18 and three quarters within 71.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.